This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drugdevelopment. According to the United Nation’s 2024 World Population Prospects data, the global population of those 65 years old and over will grow from 0.8 billion in 2023 to 1.2 billion in 2035.
This article outlines key considerations and strategies for developing a sustainable generic drugdevelopment strategy. Pfizer, for example, has been applying green chemistry principles in drugdevelopment for over two decades to reduce waste, minimize resource use, and develop energy-efficient manufacturing processes.
As the pharmaceutical industry continues to evolve, drugdevelopers encounter new challenges and opportunities in their pursuit of innovation. In response, the PPD clinical research business of Thermo Fisher Scientific conducted its third global survey of 150 drugdevelopers to capture a comprehensive view of these evolving trends.
Our annual look at the state of the drugdevelopment industry highlights a dual set of challenges complicating progress. Rising costs have become a persistent challenge for drugdevelopers, driven by a combination of internal and external pressures that have intensified in recent years.
Whether trial design, execution, or otherwise, drugdevelopment even where there is precedent is a challenging road and should not be taken for granted. Let’s agree to make 2024 the year we take action and voice concerns for legislation that encumbers the ability for biotech to deliver on its promise to patients and caregivers.
The Jackson Laboratory is offering a short MiniCourse on modeling rare diseases for preclinical drugdevelopment. The Jackson Laboratory has been integral in the development of KAND cell and mouse models, and we’re grateful for their continued dedication to advancing rare disease research.
The 2024 Nobel Prize in Chemistry was awarded to Demis Hassabis and John Jumper from Google DeepMind for developing AlphaFold2, and to David Baker from the University of Washington for his work in computational protein design. These innovations have revolutionised the understanding of protein structures using artificial intelligence.
Aditi Falnikar’s presentation from our 2023 KAND Conference Read the Article Rare Roundup FDA issues final guidance on rare disease drugdevelopment As we continue to explore new therapeutic avenues for treating KAND, it is crucial to think about the regulatory steps those therapies will face.
Your DrugsDevelopment Stage The stage of your drugdevelopment is a critical factor in selecting a CDMO. Adhering to industry standards, a preference exists for utilizing the same CDMO for both development and commercial manufacturing to enhance communication and timeline management. 2024, March 13).
Medical device industry trends for 2024. Let’s look at what is poised to impact the medical device industry in 2024. Let’s look at what is poised to impact the medical device industry in 2024. The medical device industry is in a constant state of evolution. population will be 65 and older by the year 2060.
Fierce Pharma Forward: DrugDevelopment and Delivery Insights for 2024 Join us for the inaugural Fierce Pharma Forward, a virtual event where industry leaders will explore the latest innovations in drug delivery and development. drug delivery development costs Resource Type Questex Event Fierce Pharma 250x190.png
On Sunday, May 19th, 2024, 21 individuals consisting of Perficient employees and their family members, participated in the 2024 Michigan Kidney Walk at the Detroit Zoo. This annual event aims to raise funds for the National Kidney Foundation, an organization that provides critical support to those affected by kidney disease.
As we approach the end of 2023, it’s time to reflect on the past 12 months and how advances in drugdevelopment shaped the pharma and biotech industries. These shifts are a prelude to further change and progress in the clinical trial landscape in 2024. Five Predictions for the DrugDevelopment Industry in 2024 1.
Five Promising Treatment Areas in Early-Phase DrugDevelopment in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drugdevelopment is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.
We’re thrilled to announce that Perficient has been recognized as a 2024 Top Workplace by the Atlanta Journal-Constitution ! The Top Workplace award is a testament to our exceptional work environment and incredible company culture. Not to mention, this marks the second consecutive year we have received this honor.
However, relying solely on in-house development capabilities is not always feasible for many organizations. Forrester released its Modern Application Development Services Landscape, Q3 2024 report to help businesses understand the value they can expect from modern application development (MAD) service providers and explore potential partners.
SUGCON (Sitecore User Group Conference) Europe 2024 was the second SUGCON I’ve attended, with the first just being six months ago in Minneapolis. I’ve developed real friendships with folks from literally every corner of the world and it’s only once or twice a year we get the whole “Sitecore Family” together.
It’s a new era and I can’t wait to see what this team achieves in 2024 and beyond! If you aren’t getting the value that you expect out of your current Salesforce partner, want a partner that will grow and evolve with you, and want to tie output to business outcomes, we are your partner.
Adobe Summit 2024 is right around the corner, and we’re excited to sit down with the executive director of marketing applications at Morgan Stanley Dorothy Joseph on March 27 at 11:30 A.M Register for the Exclusive Fireside Chat With Morgan Stanley If you’re attending Adobe Summit 2024, make sure to include this lunch session on your agenda.
Valentine We recently blogged about a new December 2024 draft guidance about accelerated approval (the December 2024 draft guidance). While the first topic is addressed primarily in the December 2024 draft guidance, the considerations and policies FDA articulates in the January 2025 draft guidance are also relevant.
AI in Pharma: Benefits, Risks and the Road Ahead AI is revolutionizing the drugdevelopment process, streamlining and accelerating every stage, from research to approval and marketing. This whitepaper explores the benefits and risks of AI in the pharmaceutical industry and examines its future.
Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field. In October, FDA announced seven new clinical trial grants awarded in fiscal year (FY) 2024 – including one for a Phase 3 trial – totaling $17.2 million over four years.
Nat Commun 15 , 859 (2024). link] Proteins labelled site-specifically with small molecules are valuable assets for chemical biology and drugdevelopment. The unique reactivity profile of the 1,2-aminothiol moiety of N -terminal cysteines ( N -Cys) of proteins renders it highly attractive for regioselective protein labelling.
Health insurers from every corner of the country are set to assemble in Las Vegas for the 2024 AHIP conference —and here at Perficient, we’re excited to have two of our colleagues attending as well. I think payers have an opportunity to use the mandate as a springboard for change and modernization.
png Listing Introduction Join us for an webinar on Revolutionizing DrugDevelopment: AI Innovations in Healthcare, where you'll learn about the latest advancements in leveraging artificial intelligence to transform the drugdevelopment process. On Demand Start Date Tue, 06/25/2024 - 13:00
Why is detecting cancers via liquid biopsy before they become visible on imaging important for drugdevelopment, not just diagnostics? We believe liquid biopsy is very helpful for oncology drugdevelopment because the reduction and clearance of circulating DNA occurs quickly before radiographic imaging is available.
Overcoming drugdevelopment hurdles with phase-appropriate technology transfers Discover how phase-appropriate technology transfers can help you overcome regulatory challenges, reduce costs, and accelerate your path to commercialization. jpiatt Thu, 09/05/2024 - 14:54 Facing roadblocks in drugdevelopment?
How to Optimize Your Early-Phase DrugDevelopment Program pmjackson Wed, 05/29/2024 - 20:32 The Challenges With Outsourcing DrugDevelopment In a Biopharma Dive survey, 45% of the over 143 biopharmaceutical executives surveyed cited the inability to adhere to tight deadlines as a common challenge in preclinical and Phase I clinical development.
Mini-Organs, Major Breakthroughs: How Hub Organoids Are Accelerating Oncology DrugDevelopment dwunderlin Wed, 04/03/2024 - 17:28 Tue, 05/14/2024 - 09:30 Resource Type Webinar Dr. Sylvia F. On Demand Start Date Tue, 05/14/2024 - 10:30 Click here to login. Listing Image Hub_ListingLogo_250x190.png
January 25, 2024 — Critical Path Institute (C-Path) today announced the promotion of Cécile Ollivier, M.S., January 25, 2024 — Critical Path Institute (C-Path) today announced the promotion of Cécile Ollivier, M.S., AMSTERDAM and TUCSON, Ariz., from Managing Director, Europe to Vice President of Global Affairs.
Heppner Journal of Medicinal Chemistry 2024 DOI: 10.1021/acs.jmedchem.3c01502 3c01502 Enzyme inhibitors that form covalent bonds with their targets are being increasingly pursued in drugdevelopment. Ogboo, Florian Wittlinger, Stefan A. Laufer, Erik M. Schaefer, Earl W. May, and David E.
Angie Fuller, Director, KIF1A.ORG , Angie@kif1a.org Upcoming Meetings We have some exciting meetings lined up for June: 6/11 Epilepsy Listening Session : A meeting to hear directly from parents and patients about their experience with epilepsy, the effectiveness and side effects of current treatments, and their hopes for future drugdevelopment.
Next-level personalization strategies will undoubtedly be a key topic at Salesforce’s largest event this year. Dreamforce is right around the corner taking place in San Francisco on September 17 to 19, and learning how to get the most out of your customer data with AI-powered tools is top of mind.
Listing Image PPD-TF-logo.png Listing Introduction Get the latest FSP trends, strategies, and projections for biopharma and biotech companies as Lori Boyce, Vice President, PPD FSP Solutions, and Mike Lydon, Director, PPD FSP Solutions, share findings from The 2024 FSP Trends Report. On Demand Start Date Thu, 04/11/2024 - 12:00
Engaging at the outset with a fully integrated and experienced drugdevelopment partner can ensure safety, with timely data sharing at every step of the drugdevelopment plan, and facilitate agile, flexible decision-making and planning. View the full library of The Altascientist publications. Image thumbnail-qh33.jpg
The mini documentary explores transformation in the slow-to-change drugdevelopment industry. Leaders from Altasciences dive into the obstacles and inefficiencies of the traditional outsourcing relationship between CROs and drug sponsors, and how Altasciences has broken from tradition to address these challenges.
Perficient is proud to announce that we have been recognized as Sitecore’s 2024 Practice Excellence Award Global Winner. This award recognizes Perficient for being a solution partner who is successful in building a business around their Sitecore practice, highlighting our power to adapt and grow. “We
By Sarah Wicks — On May 21, 2024, the EveryLife Foundation for Rare Diseases (ELF) will host a Scientific Workshop at the National Press Club in Washington, D.C. aimed at identifying and characterizing the challenges in developing therapies for ultra-rare diseases and conditions that affect exceedingly small populations.
Forrester’s report, The Automation Fabric Services Landscape, Q1 2024, offers insights into the evolving landscape and recognizes notable providers in the industry. You can read the entire Automatic Fabric Services Landscape Q1 2024 report via the Forrester website where it’s available to Forrester subscribers and for purchase.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content